Moderna Financial Ratios
NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Moderna ratio analysis
Moderna earned a net margin of -145.2% in FY 2025, down from -110.0% a year earlier. Gross margin was 55.3% compared with a median of 85.8% over the prior 7 years. Return on equity reached -32.6%, meaning Moderna generated -0.33 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.07 versus 0.00 the year before, and the current ratio was 3.29. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Moderna financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | 8.93 | 8.98 | — | — | — | — | — |
| Price / sales | 6.18 | 5.01 | 5.55 | 3.67 | 5.54 | 49.57 | 104.21 | 10.19 | — | — |
| Price / book | 1.39 | 1.49 | 2.74 | 3.70 | 7.24 | 15.54 | 5.32 | 0.90 | — | — |
| Gross margin | 55.3% | 54.8% | 31.5% | 71.9% | 85.8% | 99.0% | 100.0% | 100.0% | — | — |
| Operating margin | -158.1% | -121.9% | -61.9% | 48.9% | 72.0% | -95.0% | -910.0% | -306.0% | -130.9% | -206.4% |
| Net margin | -145.2% | -110.0% | -68.8% | 43.4% | 66.1% | -93.0% | -856.7% | -284.8% | -124.3% | -199.5% |
| Free cash flow margin | -106.2% | -125.3% | -55.9% | 23.8% | 72.2% | 244.0% | -818.3% | -323.3% | -189.4% | 31.0% |
| Return on equity (ROE) | -32.6% | -32.7% | -34.0% | 43.7% | 86.3% | -29.2% | -43.7% | -25.1% | — | — |
| Return on assets (ROA) | -22.9% | -25.2% | -25.6% | 32.3% | 49.5% | -10.2% | -32.3% | -19.6% | -23.6% | — |
| Debt / equity | 0.07 | 0.00 | — | — | — | — | — | — | — | — |
| Current ratio | 3.29 | 3.67 | 3.42 | 2.73 | 1.76 | 1.43 | 7.89 | 7.02 | 4.09 | — |
| Revenue growth | -39.9% | -52.7% | -64.4% | 4.3% | 2,200.2% | 1,238.3% | -55.6% | -34.4% | 89.9% | — |
| EPS growth | — | — | -161.3% | -28.9% | — | — | — | — | — | — |